Proactive therapeutic drug monitoring (TDM) during infliximab induction does not improve disease remission rates in patients with spondyloarthritis, rheumatoid arthritis (RA) or other chronic immune-mediated inflammatory diseases, a trial shows.

TDM tailors biologic therapy to individual patients by measuring serum drug levels and antidrug antibodies (ADAs), and adjusting treatment doses based on the levels, with the goal of maximising the efficacy and safety of the biologic.